68 related articles for article (PubMed ID: 6305153)
1. Structural modifications of the ergopeptine molecule and their differential influence on the affinities to different receptor binding sites--a structure affinity analysis.
Closse A; Bolliger G; Dravid A; Frick W; Hauser D; Pfäffli P; Sauter A; Tobler HJ
Adv Biochem Psychopharmacol; 1983; 36():269-79. PubMed ID: 6305153
[No Abstract] [Full Text] [Related]
2. Multiple CNS receptor interactions of ergot alkaloids: affinity and intrinsic activity analysis in in vitro binding systems.
U'Prichard DC
Adv Biochem Psychopharmacol; 1980; 23():103-15. PubMed ID: 6249089
[No Abstract] [Full Text] [Related]
3. The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites.
Goldstein M; Lew JY; Sauter A; Lieberman A
Adv Biochem Psychopharmacol; 1980; 23():75-82. PubMed ID: 7395625
[No Abstract] [Full Text] [Related]
4. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
5. The molecular architecture of ergopeptines: a basis for biological interaction.
Weber HP
Adv Biochem Psychopharmacol; 1980; 23():25-34. PubMed ID: 6249091
[No Abstract] [Full Text] [Related]
6. Interactions of ergot compounds with dopamine receptors and endocrine functions.
Flückiger E
J Neural Transm Suppl; 1983; 18():189-204. PubMed ID: 6576114
[TBL] [Abstract][Full Text] [Related]
7. The biologically active conformation of ergot alkaloids.
Kidric J; Kocjan D; Hadzi D
Experientia; 1986 Mar; 42(3):327-8. PubMed ID: 3956687
[TBL] [Abstract][Full Text] [Related]
8. On the antagonism of ergot alkaloids and dopamine by phenothiazines.
Stone TW
Experientia; 1974 Jul; 30(7):827-9. PubMed ID: 4847689
[No Abstract] [Full Text] [Related]
9. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.
Mor M; Rivara S; Silva C; Bordi F; Plazzi PV; Spadoni G; Diamantini G; Balsamini C; Tarzia G; Fraschini F; Lucini V; Nonno R; Stankov BM
J Med Chem; 1998 Sep; 41(20):3831-44. PubMed ID: 9748358
[TBL] [Abstract][Full Text] [Related]
10. Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding.
Choudhary MS; Sachs N; Uluer A; Glennon RA; Westkaemper RB; Roth BL
Mol Pharmacol; 1995 Mar; 47(3):450-7. PubMed ID: 7700242
[TBL] [Abstract][Full Text] [Related]
11. Three-dimensional quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study.
Sicsic S; Serraz I; Andrieux J; Brémont B; Mathé-Allainmat M; Poncet A; Shen S; Langlois M
J Med Chem; 1997 Feb; 40(5):739-48. PubMed ID: 9057860
[TBL] [Abstract][Full Text] [Related]
12. The influence of rigid or flexible linkage between two ligands on the effective affinity and avidity for reversible interactions with bivalent receptors.
Bobrovnik SA
J Mol Recognit; 2007; 20(4):253-62. PubMed ID: 17847051
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacological basis for the therapeutic use of ergot alkaloids].
Tran MA; Montastruc JL; Montastruc P
Presse Med; 1983 Feb; 12(8):517-20. PubMed ID: 6131414
[TBL] [Abstract][Full Text] [Related]
14. The central domain of colicin N possesses the receptor recognition site but not the binding affinity of the whole toxin.
Evans LJ; Labeit S; Cooper A; Bond LH; Lakey JH
Biochemistry; 1996 Dec; 35(48):15143-8. PubMed ID: 8952461
[TBL] [Abstract][Full Text] [Related]
15. Relationships of structure to binding of gamma-aminobutyric acid (GABA) and related compounds with the GABA and benzodiazepine receptors.
Ogawa N; Mizuno S; Tsukamoto S; Mori A
Res Commun Chem Pathol Pharmacol; 1984 Mar; 43(3):355-68. PubMed ID: 6326211
[TBL] [Abstract][Full Text] [Related]
16. Aminopyrimidines with high affinity for both serotonin and dopamine receptors.
Wustrow D; Belliotti T; Glase S; Kesten SR; Johnson D; Colbry N; Rubin R; Blackburn A; Akunne H; Corbin A; Davis MD; Georgic L; Whetzel S; Zoski K; Heffner T; Pugsley T; Wise L
J Med Chem; 1998 Feb; 41(5):760-71. PubMed ID: 9513604
[TBL] [Abstract][Full Text] [Related]
17. Specific binding of [20-3H]12-deoxyphorbol 13-isobutyrate to phorbol ester receptor subclasses in mouse skin particulate preparations.
Dunn JA; Blumberg PM
Cancer Res; 1983 Oct; 43(10):4632-7. PubMed ID: 6309373
[TBL] [Abstract][Full Text] [Related]
18. Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
Katsura Y; Zhang X; Homma K; Rice KC; Calderon SN; Rothman RB; Yamamura HI; Davis P; Flippen-Anderson JL; Xu H; Becketts K; Foltz EJ; Porreca F
J Med Chem; 1997 Aug; 40(18):2936-47. PubMed ID: 9288176
[TBL] [Abstract][Full Text] [Related]
19. [The dopaminergic mechanisms of the action of buspirone and its structural analogs].
Komissarov IV; Mamonov AB
Eksp Klin Farmakol; 1994; 57(1):63-6. PubMed ID: 8142870
[No Abstract] [Full Text] [Related]
20. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
